Crewe Advisors’s Myriad Genetics MYGN Stock Holding History

Crewe Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000	Closed	-$8.87K	–	812
2025 Q1	$8.87K	Hold	1,000	–	–	﹤0.01%	431
2024 Q4	$13.7K	Hold	1,000	–	–	﹤0.01%	399
2024 Q3	$27.4K	Hold	1,000	–	–	﹤0.01%	370
2024 Q2	$24.5K	Hold	1,000	–	–	﹤0.01%	514
2024 Q1	$21.3K	Buy	+1,000	New	+$21.5K	﹤0.01%	482

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Crewe Advisors's MYGN Position: Q2 2025 in Review

Crewe Advisors sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 1,000 shares — an estimated $8.87K sold.

Crewe Advisors first reported a position in MYGN in Q1 2024 and held it in 5 quarters. The position peaked at $27.4K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

Crewe Advisors reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
Crewe Advisors sold 1,000 Myriad Genetics shares in Q2 2025, an estimated $8.87K.
Crewe Advisors first reported a position in Myriad Genetics in Q1 2024 and held it in 5 quarters.
Crewe Advisors's Myriad Genetics position peaked at $27.4K in Q3 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Crewe Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.